Codexis (CDXS)
(Real Time Quote from BATS)
$2.90 USD
-0.08 (-2.69%)
Updated Jul 10, 2024 12:28 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
Brokerage Reports
Codexis, Inc. [CDXS]
Reports for Purchase
Showing records 21 - 40 ( 46 total )
Company: Codexis, Inc.
Industry: Industrial Services
We Expect Short-Term Impact From COVID-19; Adjust PT to $21.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Codexis, Inc.
Industry: Industrial Services
A Second Major Partnership in Novel Biotherapeutics; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Novel Biotherapeutics Come Into Spotlight; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Roche Partnership Kick-Starts Molecular Diagnostics Business; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Diversifying Business With Multiple Growth Drivers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Stronger Revenues and Two New Biotherapeutics Expected in 2H19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Novartis Licenses CodeEvolver Tech; Biotherapeutic, Food, and NGS Segments Are Expected to Grow; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
New Therapeutics Coming in 2019; Food and NGS Segments Expected to Grow; Reiterate Buy With Higher $22.50PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
What to Expect in 2019: Nestle Options, Tasteva Growth, and NGS Revenues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Positive Results From First CDX-6114 Study; Tasteva M off to a Strong Start; Higher $16.50PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
CodeEvolver Sweet Delivery Could Prove a Major Upside; Higher $16PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Focus on Biotherapeutics; CDX-6114 Results in 4Q18; Higher $15.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
CDX-6114 Ready for Phase 1; Two New Drugs By 2019; Higher $11.50PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Novel Ligase Is a Strong Contender for the NGS Market; Higher $10 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Nestle Agreement Is Likely the First of Many; NGS Enzymes to Launch in 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Nestle Agreement Validates CodeEvolver''s Potential for Drug Development; Higher $8.50 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Off-the-Shelf Enzymes Launch by YE17; Phase 1 PKU Study to Start in 1H18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Partnerships and Programs on Track; We See 2018 as an Inflection Point; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Codexis, Inc.
Industry: Industrial Services
Two New Businesses to Boost Revenues in 2018; Increasing PT to $8; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S